Reggie Edgerton joins University of Technology in Sydney Australia

Edgertonweb
SpinalCure is thrilled to announce that world-renowned neuroscientist, Professor Reggie Edgerton, will be coming to Australia to help establish a ground-breaking neurostimulation initiative for people with spinal cord injury.

The neurostimulation project will sit within the newly formed Centre for Neuroscience and Regenerative Medicine, which will be headed by SpinalCure Fellow and UTS Professor of Neuroscience, Prof. Bryce Vissel. The project is expected to commence in 2017 and is a collaborative effort between UTS, Professor Edgerton, SpinalCure Australia and Spinal Cord Injuries Australia.

Neurostimulation will form the flagship research stream of a world-leading spinal cord injury recovery program within the Centre. The program is anticipated to have six or more exciting, new research streams added over coming years.

We envision that fully established and funded, this will be the largest, most comprehensive effort to cure spinal cord injury in the Southern Hemisphere, leading the world to unprecedented levels of recovery for people with spinal cord injury.

Edgerton will retain his professorship at UCLA.

See the full announcement link HERE

Posted in Chronic Spinal Cord Injury Research, Rehabilitation | Tagged , | Leave a comment

Neurologic-Controlled Exoskeletal Neuro-Rehibilitation by Thomas Schildhauer, MD

Seattle Science Foundation

Neurologic-Controlled Exoskeletal Neuro-Rehibilitation was presented by Thomas Schildhauer, MD at the Seattle Science Foundation and Swedish Neuroscience Institute Grand Rounds. Dr. Schildhauer discusses the exciting developments in the use of the Cyberdyne robotic exoskeleton, HAL, in treatment of acute and chronic spinal cord injury.

Seattle Science Foundation is a non-profit organization dedicated to the international collaboration among physicians, scientists, technologists, engineers and educators. The Foundation’s training facilities and extensive internet connectivity have been designed to foster improvements in health care through professional medical education, training, creative dialogue and innovation.

Posted in Chronic Spinal Cord Injury Research, Rehabilitation, Spinal Research | Tagged , | Leave a comment

StemCells Inc. acquired by Israeli medical device company

StemCells Inc. has merged with Microbot Medical.  Recently, the company abandoned their spinal cord injury Phase 2 clinical trial called the Pathway Study.

See the full article HERE

Posted in Spinal Research, Stem Cell Research | Tagged | Leave a comment

Working 2 Walk 2016 Symposium

Make plans today for the annual W2W2016 Symposium!  Here’s a list of speakers and the agenda for both days (October 28th – 29th).   You don’t want to miss it!

REGISTRATION LINK IS NOW OPEN. 

CATCH THE EARLY BIRD SPECIAL THROUGH SEPTEMBER 16th!

Radisson Blu Mall of America, 2100 Killebrew Dr, Bloomington MN 55425

Radisson Blu Mall of America, 2100 Killebrew Dr, Bloomington MN 55425

Posted in Unite 2 Fight Paralysis, Working 2 Walk Science & Advocacy Symposium | Leave a comment

Direct Nerve Stimulation Webinar

This webinar introduced the latest technology applications in direct nerve stimulation for both the peripheral and central nervous systems and the published research supporting or negating them.  From the United Spinal Association Webinar Series.

Dr. Kimberly Anderson-Erisman, PhD, Research Associate Professor at the University of Miami and the Director of Education at the Miami Project to Cure Paralysis;
Jennifer French, MBA, Executive Director of the Neurotech Network and Senior Editor of Neurotech Reports.

Plan to attend the W2W 2016!
Keynote Speaker – Kim Anderson-Erisman, PhD,
University of Miami Miller School of Medicine  

Posted in Chronic Spinal Cord Injury Research, Rehabilitation, Spinal Research | Tagged , , ,

Dr. Arthur Jenkins: SCI and proposed changes

Dr. Arthur L. Jenkins III MD

Dr. Arthur L. Jenkins III MD

Dr. Arthur L. Jenkins, III MD FACS giving a TED-style talk at the NY Symposium on Neurological Emergencies and Neurocritical Care. Dr. Jenkins discusses the scope and costs of the impact of spinal cord injury on society, summarizes the current state of art for treatment, and the need to radically alter the way clinical trials are run, and where they’re run, to begin to change the way spinal cord injured patient get treated and improve.

Location: NY Academy of Medicine, New York City, NY, USA

Posted in Chronic Spinal Cord Injury Research, Regenerative Medicine, Rehabilitation, Spinal Research, Stem Cell Research | Tagged

Long-Term Studies Reveal Positive Results for Initial Phase of SCI Clinical Trial of Regenerative Medicine-Based Treatment

June 9th, Shepherd Center Atlanta Georgia AST-OPC

Asterias Biotherapeutics Inc., a California-based biotechnology company focused on regenerative medicine, recently announced positive results from long-term follow-up studies of five patients – including two treated at Shepherd Center – with thoracic-level spinal cord injury (SCI) who participated in the company’s clinical trial of an investigational product.

Results from Asterias’ Phase 1 clinical trial assessing the safety of a relatively low dose (2 million cells) of AST-OPC1 (oligodendrocyte progenitor cells) administered within 14 days of injury showed, in four of the five patients, reduced spinal cord cavitation as measured by serial MRI scans throughout the four- to five-year follow-up period.. Also, AST-OPC1 appeared to have positive long-term effects on reducing spinal cord tissue deterioration.

“This new long-term follow-up data continues to support the general safety of AST-OPC1 and indicates minimal risk of the transplanted cells having unintended effects,” said Edward Wirth III, M.D., chief medical officer for Asterias. “In detailed immune response monitoring of patients, the results are consistent with long-term cell engraftment, immune system tolerability and an absence of adverse effects. In short, AST-OPC1 does not appear to present any immunological or other long-term safety issues when administered to patients with spinal cord injuries.”

In addition, Asterias announced that recent successes in both the Phase 1 and Phase 1/2a clinical trials of AST-OPC1 supported the FDA’s recent decision to clear expansion of the current Phase 1/2a trial, named SCiStar, from 13 to up to 35 newly injured patients. In the SCiStar trial, the company and its research sites, including Shepherd Center, are testing escalating doses of AST-OPC1 that researchers believe may improve motor function in patients with cervical-level SCI.

SEE THE FULL STORY HERE FROM SHEPHERD CENTER

ASTERIAS FULL ARTICLE LINK

Posted in Chronic Spinal Cord Injury Research, Regenerative Medicine, Spinal Research, Stem Cell Research | Tagged ,

Biologists discover new strategy to treat CNS injury

UC San Diego News Center by Kim McDonald

Yimin Zou, PhD  Principal Investigator

Yimin Zou, PhD Principal Investigator


Neurobiologists at UC San Diego have discovered how signals that orchestrate the construction of the nervous system also influence recovery after traumatic injury. They also found that manipulating these signals can enhance the return of function.

Most people who suffer traumatic injuries have incomplete lesions of neural circuits whose function can be partially restored from the reconfiguration of the spared circuits with rehabilitative training. But the mechanisms are not well understood.

In this week’s issue of Nature Neuroscience, biologists at UC San Diego report that removing the gene that encodes Ryk, a cell surface receptor for signaling proteins that control the wiring of the nervous system in development, enhances the ability of adult mice to remodel their neural circuits for the recovery of fine motor control after spinal cord injury.

“Our new study now provides the first genetic evidence that those signaling proteins, important in wiring the nervous system in development, have a profound influence on how central nervous system axons respond to spinal cord injury,” said Yimin Zou, a professor in the Neurobiology Section of UC San Diego’s Division of Biological Sciences, who headed the research team. “This suggests that many other guidance cues, in addition to these signaling proteins, may also play roles in adult spinal cord repair. This opens up new opportunities to apply what we’ve learned in nervous system development to treat paralysis in adulthood.”

THE YIMIN ZOU LAB WEBSITE LINK:

SCI Awakens Developmental Signals by Sam Maddox

Ryk controls remapping of motor cortex during functional recovery after spinal cord injury. ABSTRACT

AAAS Science News: Read the full public press release at this LINK

Posted in Chronic Spinal Cord Injury Research, Regenerative Medicine, Spinal Research | Tagged

Characterizing cardiovascular autonomic dysfunction in individuals with spinal cord injury

Society for Neuroscience Chicago 2015 Nanosymposium Energy Metabolism and Cardiovascular Regulation Autonomic Regulation
Authors: *S. WANG1, S. ASLAN1,2, C. FERREIRA1, J. GUNTER1, J. WYLES1, D. WANG1, S. HARKEMA1,2; 1Dept. of Neurolog. Surgery, Univ. of Louisville, Louisville, KY; 2Neurosci. Collaborative Ctr., Frazier Rehab Inst., Louisville, KY

Recognizing the pattern of autonomic control of the heart and blood vessels is a prerequisite for an effective treatment of abnormal blood pressure (BP) regulation in individuals with spinal cord injury (SCI). The goal of this study was to characterize short-term BP and heart rate (HR) responses to orthostatic stress (sit-up test) in individuals with SCI independent of their diagnoses of sensory-motor impairment scale and level. Continuous finger BP and HR were recorded from 20 subjects with AIS scale graded A, B, C or D, and neural level ranged from C3 to T11, during 15 minutes of supine rest followed by a quick passive sit-up and 15 minutes of quiet sitting. There were diverse BP and HR responses to orthostatic stress among individuals. Specifically, 1) two had normal increases in HR and BP in response to upright position. 2) Four developed orthostatic hypotension with a normal increase in HR. 3) Six had normal increases in HR but no or inadequate BP response. 4) Two had higher than normal HR response but inadequate BP response. 5) Five had no significant HR response but had a BP response. 6) One had no HR or BP response. 7) Finally, one had unstable systolic and diastolic BP responses. We further investigated sympathetic (SNS) and parasympathetic (PNS) control of HR and SNS control of peripheral vasomotion by using indirect indexes from spectral analysis. Results showed that 1) in the four with orthostatic hypotension, responses in index of SNS modulation of vasomotion (low-frequency power of diastolic BP) were lower than other subjects, indicating impaired SNS control of vasomotion below injury level. 2) Responses in SNS modulation of vasomotion were correlated with responses in systolic BP among all subjects (r = 0.46, p < 0.05) but were not correlated with completeness of sensory-motor injury.3) In the five with no HR response but had a BP response, shift of cardiac sympatho-vagal balance to SNS dominance (low to high frequency ratio of HR power) were lower than other subjects, indicating impaired SNS control of HR in these subjects. 4) Responses in cardiac sympatho-vagal balance were correlated with HR responses among all subjects (r = 0.64, p<0.004) but were not correlated with completeness of sensory-motor injury. These results confirmed impaired SNS control of HR and peripheral vasomotion after SCI and the usefulness of indirect measures of autonomic functions to assess autonomic impairment, and also indicated the importance of recognizing the pattern of autonomic impairment in individuals with SCI independent of their diagnoses of AIS scale and neural level. Larger number of subjects is needed to further characterize the diverse pattern of autonomic regulation after SCI.

Support: Commonwealth of Kentucky Challenge for Excellence Trust Fund Leona M. and Harry B. Helmsley Charitable Trust NIH Grant 5 P30 GM103507 Craig H. Neilsen Foundation University of Louisville Foundation Jewish Hospital and St. Mary’s Foundation Kentucky Spinal Cord Injury Research Center
Disclosures: S. Wang: None. S. Aslan: None. C. Ferreira: None. J. Gunter: None. J. Wyles: None. D. Wang: None. S. Harkema: None.

Posted in Neuroscience Abstracts, Rehabilitation, Spinal Research | Tagged ,

StemCells, Inc. Announces Termination of Phase II Pathway Study Following Review of Data

NEWARK, Calif., May 31, 2016 (GLOBE NEWSWIRE) — StemCells, Inc. (STEM) (the “Company”) today announced its decision to terminate the Company’s Phase II Pathway Study in spinal cord injury following an in-depth review of data from the study and after obtaining the concurrence of the study’s Interim Analysis Data Monitoring Committee (the “IA-DMC”). While the results showed overall improvement in patients treated with the Company’s proprietary cells, the magnitude of the effect and the perceived trend of the effect over time did not justify continuing the study or exploring the variability in the initial patient observations, given the financial resources available to the Company.

READ THE FULL GLOBE NEWSWIRE STORY AT THIS LINK

The Niche: End of line for StemCells Inc., pioneering & controversial stem cell biotech:

Posted in Chronic Spinal Cord Injury Research, Regenerative Medicine, Stem Cell Research | Tagged